The positive results in 5 out of 6 patients indicate that Tiziana Life Sciences' intranasal Foralumab treatment is showing promise in treating non-active secondary progressive multiple sclerosis. This news may attract more investors, leading to increased demand for the stock and potential stock price growth in the short term.